# Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis

> **NCT00833066** · PHASE1,PHASE2 · COMPLETED · sponsor: **BioTech Tools S.A.** · enrollment: 54 (actual)

## Conditions studied

- Seasonal Allergic Rhinoconjunctivitis

## Interventions

- **BIOLOGICAL:** gpASIT+TM
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** gpASIT+TM
- **BIOLOGICAL:** gpASIT+TM

## Key facts

- **NCT ID:** NCT00833066
- **Lead sponsor:** BioTech Tools S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-10
- **Final completion:** 2009-11
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2011-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00833066

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00833066, "Safety Study of Grass Pollen-derived Peptides to Treat Seasonal Allergic Rhinoconjunctivitis". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00833066. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*